Latest Breaking News On - Monjuvi minjuvi - Page 2 : comparemela.com
PASADENA, Calif., November 07, 2023 Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced the sale of portions of financial interests from Alexion Pharmaceuticals, Inc., on sales of Ultomiris® (ravulizumab-cwvz) and from MorphoSys AG on sales of Monjuvi® (U.S.)/Minjuvi® (ex-U.S.) (tafasitamab-cxix) to OMERS, one of Canada’s largest defined benefit pension plans.
CanadaNew-yorkUnited-statesTorontoOntarioLuxembourgSydneyNew-south-walesAustraliaLondonCity-ofUnited-kingdom